The US Food and Drug Administration believes that completion of the still-ongoing reorganization of its Office of New Drugs, coupled with hiring initiatives, will improve its ability to satisfy biosimilar user fee meeting management goals in the coming years.
The FDA’s biosimilar user fee (BsUFA II) program missed fewer meeting performance goals in fiscal year 2018 compared to the...






